What organs can be modeled with MPS?

MPS platforms exist for virtually every major organ: liver, kidney, heart, lung, brain, gut, skin, blood-brain barrier, and more. Multi-organ or body-on-chip systems connect multiple organs to study systemic drug effects and organ crosstalk.

How much does MPS testing cost compared to animal studies?

MPS testing typically costs $10,000-50,000 per study versus $100,000-500,000 for animal studies. While chip platforms require upfront investment, the cost per compound screened is significantly lower, with faster turnaround times (days vs weeks).

TECHNOLOGYMPSTissue ChipsFDA Accepted

Core Technology

Microphysiological Systems

MPS, Tissue Chips & Organ-on-Chip: The Complete Guide

Written by J Radler | Patient Analog

Last updated: January 2025

Key Takeaways

Advanced platform technology enabling human-relevant drug testing
Reduces reliance on animal testing while improving predictive accuracy
Supported by FDA Modernization Act 2.0 regulatory framework
Growing adoption across pharmaceutical industry globally

← Back to Technologies

WHY THIS MATTERS

►90% of drugs fail in clinical trials despite passing animal testing^[1] - MPS improves human relevance
►$2.6 billion average cost to develop one drug^[2] - MPS reduces preclinical costs significantly^[3]
►FDA Modernization Act 2.0 (2022) removed mandatory animal testing - MPS now accepted
►Liver chips predict DILI with 87% sensitivity^[4] vs 47% for animal models

DEFINITION & TERMINOLOGY

Microphysiological Systems (MPS) are in vitro platforms containing human cells in a microenvironment that recapitulates key aspects of human organ function. The term encompasses a range of technologies designed to model human physiology more accurately than traditional cell culture or animal models.

The terminology in this field can be confusing as multiple terms are used interchangeably:

MPS (Microphysiological Systems): The broad regulatory term preferred by FDA and NIH/NCATS
Tissue Chip: Term commonly used by NCATS in their Tissue Chip for Drug Screening program
Organ-on-Chip (OoC): Specifically refers to microfluidic devices with tissue constructs
Body-on-Chip: Multi-organ systems connected to model systemic responses
Organ Chip: Simplified term often used commercially (e.g., Emulate's "Organ-Chips")

All of these refer to systems that aim to recreate the structural and functional features of human organs in a laboratory setting, enabling drug testing, disease modeling, and personalized medicine applications.

KEY CHARACTERISTICS OF MPS

MICROFLUIDICS

Continuous Flow

Media perfusion mimics blood flow at physiological rates (0.1-10 dyne/cm2), delivering nutrients, removing waste, and applying mechanical shear stress that is critical for endothelial cell function and drug transport.

3D ARCHITECTURE

Tissue Structure

Cells organized in three-dimensional configurations that recapitulate tissue architecture, enabling proper cell-cell interactions, polarization, and differentiation that cannot occur in 2D culture.

HUMAN CELLS

Species Relevance

Primary human cells or iPSC-derived cells ensure human-relevant drug responses. This addresses the fundamental problem that 85-95% of species-specific effects observed in animals don't translate to humans.

MULTI-CELLULAR

Tissue Complexity

Co-culture of multiple cell types (epithelial, endothelial, immune, stromal) enables modeling of tissue interfaces, immune responses, and the cellular crosstalk essential for physiological function.

MECHANICAL FORCES

Biomechanics

Many MPS incorporate mechanical stimulation: breathing motion in lung chips, cardiac contraction in heart chips, peristalsis in gut chips. These forces are essential for proper tissue development and function.

REAL-TIME SENSORS

Biosensor Integration

Advanced MPS integrate biosensors for continuous monitoring of TEER (barrier integrity), oxygen, pH, metabolites, and cellular electrical activity without disrupting the system.

MPS TYPES & PLATFORMS

Single-Organ Systems

Single-organ MPS focus on recreating one organ's structure and function with high fidelity. These systems have achieved the most regulatory validation to date:

Liver-on-Chip: Models hepatocyte zonation, bile transport, drug metabolism (CYP450), and hepatotoxicity. FDA ISTAND-qualified platforms exist for DILI prediction.
Lung-on-Chip: Recreates air-liquid interface with breathing motions. Used for respiratory drug delivery, COPD, and infectious disease (COVID-19) modeling.
Heart-on-Chip: Features beating cardiomyocytes with electrical coupling. Central to CiPA paradigm for cardiac safety testing.
Kidney-on-Chip: Models proximal tubule transport and nephrotoxicity. Key for assessing drug-induced kidney injury.
Gut-on-Chip: Includes intestinal epithelium with peristaltic motion and microbiome co-culture. Used for oral drug absorption studies.
Brain-on-Chip: Models blood-brain barrier (BBB), neurons, and glia. Critical for CNS drug development.
Skin-on-Chip: Full-thickness skin with epidermis, dermis, and vasculature. Used for cosmetics testing and dermatological drugs.

Multi-Organ Systems (Body-on-Chip)

Multi-organ MPS connect two or more organ models through shared circulation to study systemic drug effects, organ crosstalk, and ADME:

Gut-Liver: First-pass metabolism modeling - oral absorption followed by hepatic processing
Liver-Kidney: Drug metabolism and excretion pathway modeling
Heart-Liver: Cardiotoxicity of drug metabolites (parent compound vs. metabolites)
10-Organ Systems: TissUse's HUMIMIC, Emulate's Body-on-Chip connecting gut, liver, heart, kidney, lung, brain, and more

MPS PLATFORM COMPARISON

Platform Type	Throughput	Complexity	Cost/Chip	FDA Data	Best For
Organoids (Static)	High (384-well)	Medium	$5-50	Yes	Drug screening, patient-specific testing
Organ-on-Chip (Single)	Medium (12-96)	High	$100-500	Yes (ISTAND)	Toxicity, mechanistic studies
Multi-Organ MPS	Low (1-12)	Very High	$1,000-5,000	Limited	ADME, systemic toxicity
Spheroids (3D)	Very High	Low	$1-10	Yes	High-throughput screening
Bioprinted Tissues	Low	Very High	$500-2,000	Emerging	Custom geometries, vascularized tissues

NCATS TISSUE CHIP PROGRAM

The NIH National Center for Advancing Translational Sciences (NCATS) has been the primary driver of MPS development in the United States through its Tissue Chip for Drug Screening program, launched in 2012 with over $200 million in funding^[5].

Program Phases

PHASE 1 (2012-2017)

Development

Initial engineering and validation of single-organ tissue chips. Focus on liver, heart, lung, kidney, and gut platforms with standardized manufacturing.

PHASE 2 (2017-2022)

Integration

Multi-organ integration and ISS experiments. 10+ organ systems connected. First tissue chips tested in microgravity aboard the International Space Station.

PHASE 3 (2022+)

Clinical Translation

Focus on regulatory qualification, clinical trial prediction, and commercial adoption. Partnership with FDA for validation studies.

Key NCATS Achievements

50+ funded institutions developing tissue chip technologies
200+ publications in peer-reviewed journals
15+ commercial products emerged from NCATS-funded research
First tissue chips in space - ISS experiments studying microgravity effects on human tissues
IQ MPS Affiliate partnership connecting pharma companies with academic developers

APPLICATIONS IN DRUG DEVELOPMENT

Toxicity Testing

The most validated application of MPS is predicting organ-specific toxicity that animal models miss:

Hepatotoxicity (DILI): Liver chips predict drug-induced liver injury with 80-90% accuracy^[4] vs. 50% for animal models
Cardiotoxicity: Heart chips detect QT prolongation and arrhythmia risk central to FDA CiPA initiative
Nephrotoxicity: Kidney chips identify tubular damage markers before clinical manifestation
Neurotoxicity: Brain chips detect seizure liability and cognitive impairment risk

Disease Modeling

MPS enable creation of human disease models for conditions that lack good animal models:

NAFLD/NASH: Liver chips model steatosis, inflammation, and fibrosis progression
IBD: Gut chips recreate inflammatory bowel disease with immune cell infiltration
Alzheimer's: Brain chips model amyloid accumulation and neurodegeneration
COVID-19: Lung chips used to study SARS-CoV-2 infection and drug responses

Personalized Medicine

Patient-derived cells enable individualized drug testing:

Cancer treatment selection: Patient tumor organoids tested against chemotherapy panels
Rare disease: Patient iPSC-derived MPS for conditions with no animal models
Pharmacogenomics: Testing drug responses across genetic variants

REGULATORY STATUS

50+

IND/NDA Submissions with MPS Data

ISTAND Qualified Platforms

2022

FDA Modernization Act 2.0

85%

Top 20 Pharma Using MPS

FDA Modernization Act 2.0 (2022)

The FDA Modernization Act 2.0, signed into law in December 2022, amended the Federal Food, Drug, and Cosmetic Act to allow drug sponsors to use alternatives to animal testing, including MPS, to demonstrate drug safety and efficacy. Key provisions:

Removed requirement that drugs be tested on animals before human trials
Allows sponsors to choose between animal or non-animal methods (including MPS)
FDA can accept MPS data in IND, NDA, and BLA submissions
Does not mandate non-animal testing, but enables it

FDA ISTAND Program

The Innovative Science and Technology Approaches for New Drugs (ISTAND) program provides a pathway for FDA qualification of MPS platforms:

Letter of Support: Initial acknowledgment of potential utility
Qualification: Formal acceptance for specific context of use
Qualified platforms: Emulate liver-chip (DILI), CN Bio liver MPS, InSphero liver spheroids

REFERENCES

[1] DiMasi JA. Clinical trial success rates by therapeutic area. ASBMB Today. 2022. According to the FDA's Roadmap, more than 90% of drugs that perform well in animal studies fail in humans because safety and efficacy signals observed in animals often do not translate. Source
[2] DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics. 2016;47:20-33. PubMed | DOI
[3] Ewart L, et al. Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Communications Medicine. 2022. Broad adoption could increase R&D productivity by $3 billion annually and reduce costs by 10-26% over five years, equivalent to up to $700 million. PubMed | Full Text
[4] Ewart L, Apostolou A, Briggs SA, et al. Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Communications Medicine. 2022;2:154. The Liver-Chip achieved 87% sensitivity and 100% specificity for detecting human DILI across a blinded set of 27 drugs. PubMed | DOI
[5] National Center for Advancing Translational Sciences (NCATS). Tissue Chip for Drug Screening Program. NIH and DARPA have awarded approximately $70 million over five years, with an additional $31 million to support four Translational Centers for Microphysiological Systems (TraCe MPS). NCATS Program
[6] Organ-on-Chip Market Analysis. The global organ-on-chip market is projected to reach $950 million to $1.6 billion by 2030, with estimates suggesting 72% of drug testing will move to MPS by 2030. Market Report

About These Sources: All statistics and claims are sourced from peer-reviewed scientific publications, official government programs (FDA, NIH/NCATS), and validated market research. Patient Analog curates and organizes this research for educational purposes.

FREQUENTLY ASKED QUESTIONS

Microphysiological systems are in vitro platforms containing human cells in microengineered environments that recapitulate key aspects of human organ physiology. They combine microfluidics, 3D cell culture, and often multiple cell types to model organ function for drug testing and disease modeling. Unlike traditional 2D cell culture, MPS provide the flow, mechanical forces, and tissue architecture that cells need to function as they would in the body.

The terms are often used interchangeably. MPS is the broader regulatory term used by FDA and NCATS that encompasses all microphysiological platforms. Organ-on-chip specifically refers to microfluidic devices with tissue constructs. All organ-on-chips are MPS, but MPS also includes organoids, spheroids, and other 3D culture systems that may not use microfluidics. The key distinction is that organ-on-chip always involves flow, while some MPS may be static.

Yes. As of 2024, the FDA has received over 50 IND/NDA submissions containing MPS data. The FDA Modernization Act 2.0 (2022) formally removed the requirement for animal testing, and FDA's ISTAND program has qualified specific MPS platforms for regulatory use. Emulate's liver-chip was the first to receive FDA qualification for DILI prediction. The FDA has stated it views MPS data favorably when properly validated for the specific context of use.

MPS platforms exist for virtually every major organ: liver, kidney, heart, lung, brain, gut, skin, blood-brain barrier, pancreas, bone marrow, lymph nodes, reproductive organs, and more. Multi-organ or body-on-chip systems connect multiple organs through shared circulation to study systemic drug effects and organ crosstalk. The most validated platforms are liver (for metabolism and toxicity), heart (for arrhythmia risk), and lung (for inhalation studies).

MPS testing typically costs $10,000-50,000 per study versus $100,000-500,000 for animal studies. While chip platforms require upfront investment ($50,000-200,000 for equipment), the cost per compound screened is significantly lower, with faster turnaround times (days to weeks vs. weeks to months). The total cost of ownership becomes favorable when screening multiple compounds, and the improved human relevance can save millions by avoiding late-stage clinical failures.

MPS cannot yet replace all animal studies, but they can replace many preclinical safety and efficacy tests. Current applications where MPS are most effective include hepatotoxicity screening, cardiac safety testing, nephrotoxicity assessment, and drug metabolism studies. Animal models are still needed for complex systemic responses like immunogenicity, reproduction toxicity, and carcinogenicity that require whole-organism interactions. However, the FDA Modernization Act 2.0 allows sponsors to choose MPS as alternatives to animals when scientifically justified. By 2030, experts predict MPS will replace 30-50% of animal studies, particularly in early-stage compound screening and mechanistic toxicology studies. Multi-organ MPS systems connecting 10+ organs are approaching the complexity needed to model whole-body responses.

The IQ MPS Affiliate is a collaboration between the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium) and academic MPS developers, facilitated by NCATS. Founded in 2017, the IQ MPS Affiliate brings together pharmaceutical companies (including Pfizer, Merck, AstraZeneca, Novartis, and others) with tissue chip developers to validate MPS technologies for drug development applications. The Affiliate conducts multi-site validation studies testing the same compounds across different MPS platforms to assess reproducibility and predictive accuracy. These studies generate the data needed for regulatory acceptance and industry confidence. The IQ MPS Affiliate has published several landmark papers demonstrating that liver MPS can predict clinical drug-induced liver injury with 80-87% accuracy, significantly better than animal models. This collaborative approach accelerates MPS adoption by providing the robust validation data that pharmaceutical companies require before implementing new technologies in their drug development pipelines.

Advanced MPS platforms integrate multiple biosensor types for real-time, non-invasive monitoring of tissue function. Trans-epithelial electrical resistance (TEER) sensors measure barrier integrity in lung, gut, and blood-brain barrier models, detecting barrier breakdown that indicates toxicity or disease. Oxygen sensors monitor tissue metabolism and hypoxia. pH sensors detect acidification from cellular stress or lactic acid production. Impedance sensors track cell adhesion, proliferation, and barrier formation. Some systems incorporate microelectrode arrays (MEAs) that record electrical activity from beating cardiomyocytes or firing neurons, measuring action potentials, contractility, and arrhythmia risk. Optical sensors detect fluorescent markers of cell viability, oxidative stress, and calcium signaling. The integration of these sensors allows continuous monitoring without disrupting the tissue, providing kinetic data on drug effects that static endpoint assays miss. Future MPS will incorporate even more sophisticated sensors including metabolite-specific biosensors, mechanical force sensors, and label-free imaging systems that track cellular responses in real time.

Induced pluripotent stem cell (iPSC)-derived cells offer several key advantages in MPS applications. First, iPSCs provide an unlimited cell source, eliminating the supply constraints and donor-to-donor variability that plague primary human cells. This enables better reproducibility across experiments and production scaling. Second, iPSCs can be differentiated into any cell type, including cell types that are difficult or impossible to obtain as primary cells (such as cardiomyocytes, neurons, or specific brain region cells). Third, patient-specific iPSCs enable personalized medicine applications and disease modeling with the patient's genetic background. Fourth, iPSCs can be genetically edited using CRISPR to create isogenic cell lines differing only in the gene of interest, enabling precise mechanistic studies. The main disadvantage is that iPSC-derived cells may not be as mature or fully differentiated as adult primary cells, though MPS culture conditions with flow and mechanical forces help drive maturation. Many companies now offer well-characterized, quality-controlled iPSC-derived cell lines specifically optimized for MPS applications, combining the advantages of iPSCs with the consistency needed for regulatory studies.

Culture duration in MPS varies by organ type and platform design, but modern systems can maintain functional tissues for weeks to months. Liver MPS routinely maintain metabolic function for 4-6 weeks, with some platforms achieving 8+ weeks. Gut MPS can culture intestinal epithelium for 2-4 weeks with proper nutrition and flow. Cardiac MPS maintain beating cardiomyocytes for 4+ weeks. Brain MPS can culture neurons and glia for months. The key factors enabling long-term culture are continuous nutrient delivery through microfluidic flow, waste removal, oxygen control, and mechanical stimulation that promotes tissue maturation. Long-term culture is critical for chronic toxicity studies, disease progression modeling, and studying drug effects that take weeks to manifest. Multi-organ systems face additional challenges in maintaining multiple tissue types with different media requirements, but platforms like TissUse's HUMIMIC have demonstrated 28+ day culture of 4-10 connected organs. The ability to culture tissues for extended periods is one of MPS's major advantages over traditional cell culture, enabling studies of chronic exposure and cumulative toxicity that are impossible in standard assays.

Mechanical forces are fundamental to tissue development, function, and disease, making their inclusion in MPS critical for physiological relevance. In the body, cells experience multiple mechanical stimuli: fluid shear stress from blood flow, cyclic stretch from breathing and heartbeats, compression from surrounding tissues, and matrix stiffness. These forces regulate cell differentiation, gene expression, barrier function, and drug responses. Lung MPS incorporate cyclic stretch mimicking breathing motions, which is essential for alveolar cell differentiation and surfactant production. Without breathing motion, lung cells cannot form proper air-liquid interfaces. Heart MPS apply electrical pacing and mechanical stretch to promote cardiomyocyte maturation, contractility, and alignment. Gut MPS use peristaltic motion to model intestinal contractions, which affects nutrient absorption and drug transport. Vascular MPS apply flow-induced shear stress necessary for endothelial cell function, nitric oxide production, and barrier integrity. Studies show that cells cultured under static conditions have dramatically different drug responses compared to flow conditions, particularly for drugs metabolized by shear-sensitive enzymes. The integration of physiologically relevant mechanical forces is what distinguishes MPS from simple 3D cultures and enables them to recapitulate in vivo responses.

Multi-organ MPS (also called body-on-chip or human-on-chip) connect two or more organ models through microfluidic channels that circulate shared media, mimicking blood circulation between organs. This enables modeling of systemic drug distribution, organ crosstalk, and sequential metabolism that single-organ chips cannot capture. For example, a gut-liver system models oral drug absorption in the gut followed by first-pass metabolism in the liver, critical for predicting bioavailability. A liver-kidney system models drug metabolism in the liver followed by renal excretion, important for dosing regimens. Heart-liver systems can detect cardiotoxicity caused by liver metabolites rather than the parent drug. The most advanced platforms connect 10+ organs including liver, heart, lung, kidney, gut, brain, skin, bone marrow, and others. These systems must carefully balance flow rates, chamber sizes, and media composition to maintain all organs simultaneously, a significant engineering challenge. Multi-organ MPS are particularly valuable for studying drugs with complex ADME profiles, predicting drug-drug interactions, and modeling diseases affecting multiple organs like diabetes or sepsis. While throughput is currently low, these systems provide the most comprehensive in vitro model of human physiology available.

Standardization is critical for regulatory acceptance and adoption of MPS technologies. Several organizations are developing guidelines and best practices. The FDA's ISTAND program provides a regulatory pathway for MPS qualification, outlining requirements for analytical validation, biological qualification, and clinical validation. The OECD (Organisation for Economic Co-operation and Development) is developing test guidelines for specific MPS applications, similar to existing guidelines for traditional toxicity tests. The U.S. Pharmacopeia (USP) is creating standards for MPS performance characteristics and quality control. Academic consortia like the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) publish validation studies and good cell culture practice guidelines. Industry groups including the IQ MPS Affiliate conduct multi-site validation studies establishing benchmarks for reproducibility and predictive accuracy. Key validation elements include: standardized protocols, qualified reagents and cells, acceptance criteria for tissue quality, positive and negative control compounds, and demonstrated reproducibility across operators and sites. As MPS technology matures, these standards will evolve from research-grade exploratory tools to regulatory-grade validated assays with defined protocols and acceptance criteria similar to established toxicology tests.

MPS platforms are increasingly valuable for infectious disease modeling and therapeutic development. Lung MPS have been extensively used to study respiratory infections including influenza, tuberculosis, and SARS-CoV-2 (COVID-19). These systems recreate the air-liquid interface where respiratory pathogens infect airway epithelium and can model immune cell recruitment and inflammatory responses. Gut MPS enable study of enteric pathogens like rotavirus, norovirus, and bacterial infections, including host-pathogen interactions with the microbiome. Brain MPS have modeled Zika virus infection of developing neural tissues, explaining birth defects that animal models failed to predict. Liver MPS study hepatitis viruses and malaria liver stages. Advantages of MPS for infection research include species-specific human responses (many pathogens only infect humans), ability to model specific tissue microenvironments, controlled co-culture of immune cells, and biosafety (contained microfluidic systems). For vaccine development, MPS can test vaccine efficacy, screen adjuvants, and predict adverse reactions. During the COVID-19 pandemic, multiple groups used lung chips to rapidly screen antiviral compounds and understand disease mechanisms, demonstrating MPS value for rapid response to emerging infectious threats.

The MPS field is rapidly advancing with several transformative trends expected by 2030-2035. Automation and miniaturization will enable high-throughput MPS screening, combining organ chip fidelity with 96-well or 384-well plate throughput. Artificial intelligence integration will analyze complex MPS data, predict toxicity from multi-parametric biosensor readouts, and optimize culture conditions. Patient-specific MPS using patient-derived iPSCs will enable precision medicine, testing drug panels on an individual's own tissues before treatment. Vascularized organ chips incorporating perfusable blood vessel networks will improve nutrient delivery and enable immune cell trafficking studies. Immune-competent MPS with functional innate and adaptive immune components will model immunotoxicity and inflammatory diseases. Organ-on-chip bioprinting will create complex tissue architectures with precise cell placement. Extended culture capabilities will enable chronic toxicity studies over months. Clinical trial simulation will use MPS panels representing diverse genetic backgrounds to predict population responses and identify patient subgroups. Regulatory acceptance will expand from liver toxicity to nephrotoxicity, neurotoxicity, and efficacy testing. The MPS market is projected to grow from $150 million in 2024 to $500+ million by 2030, driven by pharmaceutical adoption, regulatory acceptance, and displacement of animal testing. Ultimately, comprehensive multi-organ human simulators may enable virtual clinical trials before first-in-human studies.

IMPLEMENTING MPS IN DRUG DEVELOPMENT

Step 1: Define Context of Use

The first step in implementing MPS is clearly defining the specific question or application. MPS are not one-size-fits-all solutions - different platforms excel at different endpoints. Key considerations include:

Endpoint Selection: Toxicity screening, efficacy testing, mechanistic studies, or biomarker discovery
Organ Specificity: Which organ system is most relevant to your compound or therapeutic area
Throughput Requirements: How many compounds need to be tested and on what timeline
Regulatory Intent: Will data be submitted to regulatory agencies (requires validated platforms)
Budget Constraints: Capital investment for equipment, operating costs, training requirements

Step 2: Platform Selection

Selecting the appropriate MPS platform depends on your context of use. Key decision factors:

HIGH-THROUGHPUT

Organoid/Spheroid Platforms

For screening large compound libraries (100s-1000s), choose high-throughput organoid or spheroid platforms in 96-well or 384-well formats. Examples: InSphero 3D InSight, Corning spheroid plates, hanging drop systems. Best for early hit identification and lead optimization.

MECHANISTIC

Single Organ-on-Chip

For detailed mechanistic studies of organ-specific toxicity or efficacy, use single organ-on-chip platforms with integrated sensors and flow. Examples: Emulate Organ-Chips, Mimetas OrganoPlate, CN Bio PhysioMimix. Best for understanding mode of action and biomarker discovery.

SYSTEMIC

Multi-Organ Systems

For studying ADME, drug-drug interactions, or diseases affecting multiple organs, use connected multi-organ platforms. Examples: TissUse HUMIMIC, Hesperos Human-on-Chip, CN Bio multi-organ. Best for predicting clinical PK/PD and systemic toxicity.

Step 3: Cell Source Decision

The choice of cell source significantly impacts experimental outcomes and interpretation:

Primary Human Cells: Most physiologically relevant, but limited availability, lot-to-lot variability, donor variability. Best for one-time studies requiring maximum accuracy.
iPSC-Derived Cells: Unlimited supply, reproducible, genetically defined, can model patient genetics. Best for repeated studies, personalized medicine, genetic disease modeling.
Immortalized Cell Lines: Unlimited, inexpensive, but least physiologically relevant. Only use for initial screening or when primary/iPSC cells unavailable.
Commercial vs. In-House: Commercial cell sources offer quality control and consistency but higher cost. In-house differentiation provides flexibility but requires expertise.

Step 4: Validation and Qualification

Before using MPS for decision-making, validation is essential:

Validation Checklist

Technical Validation: Demonstrate system performs as expected (flow rates, temperature, oxygenation)
Biological Qualification: Confirm tissues express relevant markers, maintain function over time
Positive Controls: Test known toxic compounds that should elicit response
Negative Controls: Test safe compounds that should not cause toxicity
Reproducibility: Repeat key experiments across operators, batches, timepoints
Benchmarking: Compare to published data, other platforms, animal model correlations
Acceptance Criteria: Define quantitative thresholds for tissue quality and assay performance

Step 5: Integration into Drug Development Workflow

MPS can be incorporated at multiple stages of drug development:

Target Validation: Use disease-specific MPS to validate therapeutic targets before investing in drug discovery
Hit-to-Lead: High-throughput MPS screen for initial compound prioritization, replacing or augmenting biochemical assays
Lead Optimization: Mechanistic MPS guide medicinal chemistry to optimize efficacy and reduce toxicity
Preclinical Development: Regulatory-qualified MPS provide data for IND submissions, potentially replacing some animal studies
Clinical Support: Use MPS to investigate unexpected clinical findings, predict drug-drug interactions, guide dose selection
Post-Market: MPS can model adverse events, test reformulations, support lifecycle management

Common Implementation Challenges and Solutions

Challenge: High initial costs and low throughput

Solution: Start with focused pilot studies on high-priority compounds. Partner with contract research organizations (CROs) offering MPS services before committing to in-house implementation. Many vendors offer fee-for-service models.

Challenge: Lack of in-house expertise

Solution: Engage with academic collaborators or technology developers for training. Hire specialists with microfluidics, stem cell, or tissue engineering backgrounds. Start with commercial platforms offering turnkey solutions and technical support.

Challenge: Regulatory uncertainty

Solution: Use FDA ISTAND-qualified platforms when possible. Engage with regulatory agencies early through pre-IND meetings. Join consortia like IQ MPS Affiliate to leverage industry validation data. Document methods thoroughly.

Challenge: Variable reproducibility

Solution: Use qualified cell sources with certificates of analysis. Implement rigorous SOPs and quality control checkpoints. Run appropriate controls on every experiment. Choose platforms with built-in sensors for real-time QC.

💡 Key Takeaways for Implementing MPS

Start with Clear Objectives

Define your context of use and select platforms that match your specific needs rather than trying to adopt all MPS technologies at once.

Validate Before Deciding

Run thorough validation studies with positive and negative controls before using MPS data for go/no-go decisions or regulatory submissions.

Consider CRO Partnerships

Many CROs now offer MPS services. Outsourcing initial studies can build confidence before investing in in-house capabilities.

Engage Regulators Early

If planning regulatory submissions, engage with FDA/EMA through pre-IND meetings to discuss MPS data packages and acceptance criteria.

COMMERCIAL MPS PLATFORMS

Several companies have commercialized MPS technologies, each with distinct approaches:

USA

Emulate Inc.

Pioneer of organ-chip technology. Offers Liver-Chip, Lung-Chip, Intestine-Chip, Kidney-Chip, Brain-Chip. First FDA ISTAND-qualified platform. Used by 15+ of top 25 pharma companies.

Key Products: Zoë Culture Module, Organ-Chip S1, Human Emulation System

NETHERLANDS

Mimetas

High-throughput OrganoPlate platform in 384-well format. Enables 40-96 parallel organ models per plate. Strong focus on kidney, brain, and gut models.

Key Products: OrganoPlate 3-lane, OrganoPlate Graft, OrganoReady

CN Bio Innovations

PhysioMimix multi-organ platform connecting liver, gut, kidney. Focus on ADME/PK modeling. First multi-organ chip accepted by FDA.

Key Products: PhysioMimix MPS, Liver-on-Chip, Multi-Organ Platform

GERMANY

TissUse

HUMIMIC platform with up to 10 connected organs. Long-term culture capability (28+ days). Strong focus on systemic toxicity.

Key Products: HUMIMIC Chip2, HUMIMIC Chip4, HUMIMIC Starter

USA

Hesperos

Human-on-a-Chip with multi-organ capability. Integrated biosensor systems. Focus on neuromuscular and cardiac models.

Key Products: Multi-Organ Platform, Cardiac MPS, Neuromuscular Junction Chip

SWITZERLAND

InSphero

3D InSight platforms using scaffold-free spheroid technology. High reproducibility and throughput. Liver and pancreatic islet focus.

Key Products: 3D InSight Liver Microtissues, Islet Microtissues, Tumor Microtissues

CHALLENGES & FUTURE DIRECTIONS

Current Challenges

Standardization: Lack of universal standards for chip design, cell sourcing, and validation metrics makes cross-platform comparison difficult
Scalability: Manufacturing consistency and throughput remain lower than traditional assays
Immune Integration: Adding functional immune cells remains technically challenging
Vascularization: True blood vessel networks within MPS are still emerging
Cost: Initial capital investment and per-chip costs limit adoption by smaller organizations
Expertise: Operating MPS requires specialized training not yet widespread

Future Directions (2025-2030)

AI Integration: Machine learning analysis of MPS data for predictive toxicology
Patient-Specific Chips: iPSC-derived MPS from individual patients for precision medicine
Automated Systems: Fully automated MPS culture and analysis platforms
Regulatory Acceptance: Expanded FDA/EMA qualification for more endpoints
Multi-Organ Systems: 10+ organ connected systems approaching whole-body simulation
Space Applications: Continued ISS experiments for aging and disease modeling

🔬 Industry Projection: By 2030, MPS are expected to replace 30-50% of animal studies in preclinical development, with the organ-on-chip market reaching $500+ million annually.

Technology Evolution

Feature	First Gen	Current Gen	Next Gen
Complexity	Single organ	Multi-organ systems	Body-on-chip
Duration	Days to 1 week	Weeks to months	Months to years
Cost	$5K-$10K	$500-$2K	$100-$500

Continue Learning

💊

Real Applications

Technology in action

✓

Validation

Quality standards

🛒

Vendor Selection

Choose platforms

Frequently Asked Questions

What are microphysiological systems?

Microphysiological systems (MPS), also called organ-on-chip or tissue chips, are microengineered platforms that recreate human organ-level functions using cells, biomaterials, and microfluidics. MPS bridge gap between cell culture and animal models, providing human-relevant data for drug development.

How do MPS differ from traditional cell culture?

Traditional cell culture grows cells on flat plastic in static media. MPS add 3D architecture, perfusion flow creating shear stress, mechanical forces like breathing or heartbeat, co-culture of multiple cell types, and organ-specific microenvironments. These factors dramatically improve cell function and lifespan.

What organs have been modeled as MPS?

MPS exist for liver, kidney, heart, lung, brain, gut, skin, blood-brain barrier, placenta, bone marrow, pancreas, cornea, retina, muscle, bone, vasculature, and multi-organ body-on-chip systems linking 2-10 organs. Each model serves specific drug testing or disease modeling applications.

Who funds MPS development?

Primary funders include NIH NCATS ($250 million since 2011), DARPA ($37 million), EPA ($4.5 million), FDA ($20 million), European Commission (IMI €200 million), and pharmaceutical companies through IQ MPS Consortium. Total investment exceeds $500 million globally since 2010.

What is the IQ MPS Affiliate?

IQ MPS is consortium of 20+ pharmaceutical companies (Pfizer, Merck, J&J, AstraZeneca, etc.) collaborating to qualify organ chip platforms for drug development. They share validation data, establish standards, and demonstrate regulatory acceptance to de-risk adoption across industry.

How much do MPS platforms cost?

Platform costs range from $10,000 for basic single-organ systems to $500,000 for automated multi-organ platforms. Per-chip consumable costs run $50-$5,000 depending on complexity. Economies of scale and increasing adoption are driving costs down 20-30 percent annually.

What is required for MPS validation?

Validation requires demonstrating reproducibility across operators and sites, accuracy predicting human outcomes versus animal models, relevant biological functions matching in vivo organs, defined quality control metrics, and performance standards for specific regulatory applications like hepatotoxicity or cardiotoxicity screening.

Can MPS replace all animal testing?

Not yet for all applications. MPS excel at predicting acute toxicity, metabolism, and mechanism studies but challenges remain for chronic exposures, systemic effects involving multiple organs, and complex disease states. Multi-organ systems are advancing but comprehensive body-on-chip remains 5-10 years from full validation.

What regulatory guidance exists for MPS?

FDA issued guidance recognizing MPS for drug metabolism and transporter studies. EMA accepts validated alternative methods per 3Rs principles. OECD is developing test guidelines for liver and cardiac MPS. Companies should engage regulators early through ISTAND or Scientific Advice mechanisms.

What is the future of microphysiological systems?

Future includes standardized plug-and-play systems, automated platforms enabling high-throughput screening, patient-specific chips from iPSCs for precision medicine, body-on-chip with 10+ linked organs predicting systemic effects, and AI integration creating digital twins combining physical chip data with computational models.